ClinicalTrials.gg
Status unknownNCT02972320Updated Nov 23, 2016

Extensive Stage Sclc Patients Who Were Benefit From First-line Treatment Accept Temozolomide Maintain Therapeutic

A Phase 2 interventional study of temozolomide in Extensive Stage Small Cell Lung Cancer, sponsored by Yunpeng Liu. Status unknown at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-11-23.

Sponsored by Yunpeng Liu · Phase 2, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Nov 2016), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing temozolomide in Small Cell Lung Carcinoma — 2 open to participants now, 4 under way, none of them phase 3. Temozolomide · Small Cell Lung Carcinoma.

Planned enrollment
5th of 13
60 · median 59
Started
2016
the only one that year
Phase 2
8 of 13
1 open now
Registered
7th of 13
by date
Lead sponsor
1 of 13
Yunpeng Liu

Among the 13 studies testing temozolomide in Small Cell Lung Carcinoma, this one is the 5th largest by planned enrollment, is the only one that started in 2016, is one of 8 in phase 2, and was the 7th registered.

Small Cell Lung Carcinoma

1,303 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

2 of the 13 studies testing temozolomide in Small Cell Lung Carcinoma are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About temozolomide

Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 176 (66%) set no upper age limit and 65 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing temozolomide in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

This study evaluates temozolomide maintain therapeutic efficacy and safety in extensive stage SCLC who has clinical benefit from etoposide combined Los platinum (EL) scheme in the first line treatment.

Read the detailed description

According to the etoposide combined Los platinum (EL) plan administration, every cycle was 21 days, a total of four cycle. The patients who was clinical benefit directly from EL scheme in the first line treatment accept temozolomide maintenance therapy, 150mg / m2, oral D1-5. A period of 28 days, regular follow-up and evaluation of effectiveness, safety and quality of life.

03

Conditions studied

  • Extensive Stage Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. aged 18 to 70 years old, men and women are not limited;
  2. confirmed by histopathological examination SCLC;
  3. clinical stage for patients with extensive stage (except for the case of pleural effusion)
  4. patients has no drug treatment history
  5. the implementation of palliative radiotherapy for lesions, surgical treatment, after the end of treatment over 14 days.
  6. there can be measured lesions (non radiation exposure site) of patients () evaluation;
  7. physical condition score PS:0-1
  8. more than expected survival time over 3 months

Exclusion criteria

Exclusion Criteria:

  1. the previous platinum compounds have a history of allergies;
  2. active ulcer patients;
  3. Patients with primary lung lesions were treated with radiotherapy;
  4. chest X-ray showed clear interstitial pneumonia or patients with pulmonary fibrosis;
  5. the need for treatment of in the active phase
  6. there are more serious tumor invasion, superior vena cava syndrome, or in the middle volume of malignant pleural effusion, abdominal effusion or pericardial effusion, not yet control;
  7. there is a serious infection, ADH abnormal secretion syndrome, poor control of diabetes,the need for the treatment of patients with severe complications such as vena cava syndrome
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    temozolomide maintain therapeutic

    Lobaplatin combined with etoposide for first-line treatment of extensive stage small cell lung cancer,then clinical benefit patients for temozolomide maintain therapeutic.This study have only one arm which temozolomide maintain at dose of 150mg/m2 D1-5 Q4W.

    Drug: temozolomide

Interventions

  • temozolomide maintain therapeutic

    Also known as: Temozolomide Capsule

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival in the first line of chemotherapy

    The first day of treatment to the date that disease progression is reported

    Time frame: 6 months

Secondary outcomes

  1. Overall Survival (OS)

    The first day of treatment to death or last survival confirm date

    Time frame: 3 years

  2. Tumor Response Rate (RR)

    The ratio between the number of responders and number of patients assessable for tumor response.

    Time frame: 3 months

  3. Treatment-related adverse events

    Treatment-related adverse events are assessed by common terminology criteria for adverse events (CTCAE) V4.0.

    Time frame: the first date of treatment to 30 days after the last dose of study drug, assessed up to 6 months

07

Study locations

1 of 1 sites recruiting
  • The First Affiliated Hospital of China Medical University
    Shenyang, Liaoning 110001, China
    Recruiting
    • mingfang zhao, professor · Contact13644055129
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2016, a primary completion of Dec 2017 and a completion of Dec 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2016
First posted
Nov 23, 2016
Start
Jun 2016
Primary completionEst.
Dec 2017
CompletionEst.
Dec 2018
Last update
Nov 23, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 23, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02972320
Lead sponsor
Yunpeng Liu
Responsible party
Yunpeng Liu (Director, clinical research, China Medical University, China) — Sponsor-investigator
First posted
Nov 23, 2016
Start date
Jun 2016
Primary completion
Dec 2017 (estimated)
Completion
Dec 2018 (estimated)
Last update
Nov 23, 2016

Study contacts

mingfang zhao, professor
Contact
zhaomf618@126.com
13644055129

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Temozolomide

Start the discussion